Valenzuela Daniel A, Groth Sylvia, Taubenslag Kenneth J, Gangaputra Sapna
Vanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, TN, USA.
Am J Ophthalmol Case Rep. 2021 Dec;24:101200. doi: 10.1016/j.ajoc.2021.101200. Epub 2021 Sep 1.
To describe a case of acute macular neuroretinopathy (AMN) in a patient immediately following administration of the Pfizer-BioNTech COVID-19 vaccine.
The patient complained of paracentral scotoma supported by paracentral visual field loss on multiple Humphrey visual fields that corresponded to outer retinal pathology on optical coherence tomography. The patient's symptoms resolved without treatment.
We conclude that the clinical testing demonstrated findings consistent with AMN. AMN may be an exceedingly rare adverse ocular effect of a novel vaccine and likely only in the setting of multiple other risk factors. Despite this, we strongly recommend vaccination against COVID-19.
描述一名患者在接种辉瑞-生物科技公司新冠疫苗后立即发生急性黄斑神经视网膜病变（AMN）的病例。
患者主诉旁中心暗点，多次 Humphrey 视野检查显示旁中心视野缺损，光学相干断层扫描显示对应于外层视网膜病变。患者症状未经治疗即缓解。
我们得出结论，临床检查结果与 AMN 一致。AMN 可能是一种新型疫苗极其罕见的眼部不良反应，可能仅在存在多种其他风险因素的情况下发生。尽管如此，我们强烈建议接种新冠疫苗。
